Aytu BioScience Inc (AYTU)vsHaleon plc (HLN)
AYTU
Aytu BioScience Inc
$1.99
-2.93%
HEALTHCARE · Cap: $21.36M
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 19604% more annual revenue ($11.15B vs $56.60M). HLN leads profitability with a 14.5% profit margin vs -60.2%. HLN earns a higher WallStSmart Score of 51/100 (C-).
AYTU
Avoid34
out of 100
Grade: F
HLN
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -96.9% — below average capital efficiency
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AYTU
The strongest argument for AYTU centers on Price/Book.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : AYTU
The primary concerns for AYTU are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
AYTU profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
AYTU carries more volatility with a beta of 0.27 — expect wider price swings.
HLN is growing revenue faster at 2.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aytu BioScience Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and marketing novel products in the field of hypogonadism (low testosterone levels), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company is headquartered in Englewood, Colorado.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?